Learn More About TIL Therapy

The Food and Drug Administration has approved the first one-time cellular therapy for a solid tumor. TIL, or tumor-infiltrating lymphocyte therapy, is now available for patients with metastatic melanoma whose disease has been previously treated with a PD-1 inhibitor or a BRAF inhibitor with or without a MEK inhibitor.

Patrick Hwu, MD, president and CEO of Moffitt Cancer Center, takes a closer look at TIL therapy and how it works.